AUTOANTIGEN VACCINATION IN INDIVIDUALS WITH NEW ONSET TYPE 1 DIABETES MELLITUS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目是一项先导性研究，旨在探讨胰岛素B链在人类不完全弗氏佐剂(IFA)中预防或延缓1型糖尿病临床发病后β细胞质量进一步丧失的安全性、有效性和免疫学机制。在不同的自身免疫性疾病中使用自身抗原免疫似乎是治疗人类和动物的一种新的、有效的方法。 6名受试者单次注射IBC-VS01，6名受试者单次注射IBC-VS01液体部分，其中不混合胰岛素。如果没有这块胰岛素，这种名为VSO2的注射预计不会有任何效果。注射后，12名受试者被跟踪两年，观察IBC-VS01和VSO2对糖尿病病程的影响，以及与VS02相比，IBC-VS01对受试者是否有任何不良影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is a pilot study to investigate the safety, efficacy and the immunologic mechanisms of insulin B-chain in incomplete Freund's adjuvant (IFA) in humans to prevent or delay further loss of beta cell mass after the clinical onset of Type 1 diabetes mellitus. Immunization with autoantigens in different autoimmune diseases appear to be a new, effective approach to treatment in humans and animals alike. Six subjects were given a single injection of IBC-VS01 and six subjects were given a single injection of the fluid part of IBC-VS01 without the piece of insulin mixed in it. Without the piece of insulin, this injection called (VSO2) is expected to have no effect. After the injection the 12 subjects are followed for two years to see what effects IBC-VS01 and VSO2 have on the course of diabetes and whether IBC-VS01 has any ill effects in subjects compared to VS02.